{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:11:18Z","timestamp":1792789878575,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a major cause of dose reduction, drug modification, or drug discontinuation in cancer patients which negatively impacts the overall well-being of cancer patients and medication procedures. This systematic review and meta-analysis investigation aimed to determine the global prevalence of CIPN in cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Various scientific databases (PubMed, Scopus, Web of Science, Embase, ScienceDirect, and Google Scholar) were systematically searched (by July 2023) for published studies reporting the CIPN prevalence. Meta-analysis was applied based on the Random Effect model and subgrouping was considered using the CIPN scales. Also, the heterogeneity was assessed based on the I\n                      <jats:sup>2<\/jats:sup>\n                      index.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following the assessment of 49 eligible studies (n:33,667 participants), the overall CIPN prevalence was reported 51.9% (95% CI: 45-58.7). According to the Composite Scales tool, the highest CIPN prevalence was 69.6% (95%CI: 50\u201384).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of CIPN in cancer patients was found at a high level. According to the high number of cancer survivors, the integration of necessary clinical strategies for screening, prevention, and treatment of CIPN into consistent clinical guidelines is strictly recommended. Probably these guidelines can reduce the CIPN occurrence and cancer treatment costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04256-y","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:42:08Z","timestamp":1770381728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The global prevalence of peripheral neuropathy following chemotherapy in cancer patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Nader","family":"Salari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh Galehdari","family":"Fard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Abdolmaleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadis","family":"Mosafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamarina","family":"Shohaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-8300","authenticated-orcid":false,"given":"Masoud","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"1","key":"4256_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"Ca Cancer J Clin"},{"key":"4256_CR2","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","DOI":"10.3322\/caac.21834"},{"issue":"6","key":"4256_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","volume":"20","author":"R Zaj\u0105czkowska","year":"2019","unstructured":"Zaj\u0105czkowska R, Kocot-K\u0119pska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4256_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017;81(6):772\u201381. https:\/\/doi.org\/10.1002\/ana.24951.","journal-title":"Ann Neurol"},{"issue":"9","key":"4256_CR5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s11864-022-01008-5","volume":"23","author":"MC Riesco-Martinez","year":"2022","unstructured":"Riesco-Martinez MC, Modrego A, Espinosa-Olarte P, La Salvia A, Garcia-Carbonero R. Perioperative chemotherapy for liver metastasis of colorectal cancer: lessons learned and future perspectives. Curr Treat Options Oncol. 2022;23(9):1320\u201337.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"4256_CR6","doi-asserted-by":"publisher","first-page":"e12531","DOI":"10.1111\/jjns.12531","volume":"20","author":"CF Hsieh","year":"2023","unstructured":"Hsieh CF, Chan YN, Wu CJ, Yen LY, Chang YC, Wang YJ. Patient-reported motor chemotherapy-induced peripheral neuropathy impacts function in advanced colorectal cancer survivors receiving chemotherapy: A cross-sectional study. Japan J Nurs Science: JJNS. 2023;20(3):e12531.","journal-title":"Japan J Nurs Science: JJNS"},{"issue":"3","key":"4256_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/0284186X.2021.2007283","volume":"61","author":"SW Nielsen","year":"2022","unstructured":"Nielsen SW, Eckhoff L, Ruhlmann CHB, Herrstedt J, Dalton SO. The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer\u2013a population-based cross-sectional study. Acta Oncol. 2022;61(3):363\u201370.","journal-title":"Acta Oncol"},{"issue":"3","key":"4256_CR8","doi-asserted-by":"publisher","first-page":"e29550","DOI":"10.1002\/pbc.29550","volume":"69","author":"RL Rodwin","year":"2022","unstructured":"Rodwin RL, Ross WL, Rotatori J, Allen K, Auerbach C, Balsamo LM, et al. Newly identified chemotherapy-induced peripheral neuropathy in a childhood cancer survivorship clinic. Pediatr Blood Cancer. 2022;69(3):e29550.","journal-title":"Pediatr Blood Cancer"},{"issue":"34","key":"4256_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2152\/jmi.68.232","volume":"68","author":"DA Tunjungsari","year":"2021","unstructured":"Tunjungsari DA, Gunawan PI, Ugrasena IDG. Risk factors of vincristine-induced peripheral neuropathy in acute lymphoblastic leukaemia children. J Med Invest. 2021;68(34):232\u20137.","journal-title":"J Med Invest"},{"issue":"12","key":"4256_CR10","first-page":"5933","volume":"28","author":"CS Bonhof","year":"2020","unstructured":"Bonhof CS, Trompetter HR, Vreugdenhil G, van de Poll-Franse LV, Mols F. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry. Supportive Care Cancer: Official J Multinational Association Supportive Care Cancer. 2020;28(12):5933\u201341.","journal-title":"Supportive Care Cancer: Official J Multinational Association Supportive Care Cancer"},{"key":"4256_CR11","first-page":"v49","volume":"16","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie G, Sena E, Ramnarine S, Grant R, Macleod M, et al. Incidence, prevalence and predictors of chemotherapy induced peripheral neuropathy: A systematic review and meta-analysis. Neurooncology. 2014;16:v49.","journal-title":"Neurooncology"},{"key":"4256_CR12","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"key":"4256_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK-L Lo","year":"2014","unstructured":"Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:1\u20135.","journal-title":"BMC Med Res Methodol"},{"key":"4256_CR14","doi-asserted-by":"crossref","unstructured":"Ben Kridis W, Toumi N, Khanfir A. Chemotherapy-induced peripheral neurotoxicity: single-centre prospective study. BMJ supportive & palliative care; 2023.","DOI":"10.1136\/spcare-2023-004332"},{"issue":"5","key":"4256_CR15","first-page":"421","volume":"49","author":"SF Sheikh-Wu","year":"2022","unstructured":"Sheikh-Wu SF, Anglade D, Gattamorta KA, Xiao C, Downs CA. Symptom Occurrence, Frequency, and severity during acute colorectal cancer survivorship. Oncol Nurs Forum. 2022;49(5):421\u201331.","journal-title":"Oncol Nurs Forum"},{"key":"4256_CR16","doi-asserted-by":"crossref","unstructured":"Frigotto KG, Garcia GSB, de Almeida Valviesse VRG, Pires KL. Clinical prevalence of chemotherapy-induced peripheral neuropathy in onco-hematological patients. 2021.","DOI":"10.21203\/rs.3.rs-1128753\/v1"},{"issue":"7","key":"4256_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.6004\/jnccn.2021.7026","volume":"19","author":"E Battaglini","year":"2021","unstructured":"Battaglini E, Goldstein D, Grimison P, McCullough S, Mendoza-Jones P, Park SB. Chemotherapy-Induced peripheral neurotoxicity in cancer survivors: predictors of Long-Term patient outcomes. J Natl Compr Cancer Network: JNCCN. 2021;19(7):821\u20138.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"1","key":"4256_CR18","doi-asserted-by":"crossref","first-page":"SP30","DOI":"10.37765\/ajmc.2021.88574","volume":"27","author":"BL Brady","year":"2021","unstructured":"Brady BL, Lucci M, Wilson K, Fox KM, Wojtynek J, Cooper C, et al. Clinical and economic burden of intravenous Paclitaxel or nab-paclitaxel for metastatic breast cancer. Am J Manag Care. 2021;27(1):SP30\u20136.","journal-title":"Am J Manag Care"},{"issue":"24","key":"4256_CR19","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djp413","volume":"101","author":"M Brydoy","year":"2009","unstructured":"Brydoy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Observational study of prevalence of Long-term Raynaud-Like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101(24):1682\u201395.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4256_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","volume":"125","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Weimer LH, Wang AT, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant Paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767\u201374.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4256_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ygyno.2019.08.009","volume":"155","author":"K Webber","year":"2019","unstructured":"Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, et al. OVQUEST \u2013 Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. Gynecol Oncol. 2019;155(1):126\u201334.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"4256_CR22","first-page":"2921","volume":"27","author":"S Ponce","year":"2019","unstructured":"Ponce S, Yuste A, Esquivias A, Leal A, Villoria J. A cross-sectional, comparative, syndromic description of oncological mixed pain in medical oncology units in Spain. Support Care Cancer. 2019;27(8):2921\u201331.","journal-title":"Support Care Cancer"},{"issue":"4","key":"4256_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11764-019-00769-7","volume":"13","author":"JM McCrary","year":"2019","unstructured":"McCrary JM, Goldstein D, Wyld D, Henderson R, Lewis CR, Park SB. Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. J Cancer Survivorship. 2019;13(4):495\u2013502.","journal-title":"J Cancer Survivorship"},{"issue":"8","key":"4256_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.6004\/jnccn.2019.7290","volume":"17","author":"JM McCrary","year":"2019","unstructured":"McCrary JM, Goldstein D, Trinh T, Timmins HC, Li T, Menant J, et al. Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments. JNCCN J Natl Compr Cancer Netw. 2019;17(8):949\u201355.","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"issue":"3","key":"4256_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.33588\/rn.6903.2019035","volume":"69","author":"JW Mart\u00ednez","year":"2019","unstructured":"Mart\u00ednez JW, S\u00e1nchez-Naranjo JC, Londo\u00f1o-De Los R\u00edos PA, Isaza-Mej\u00eda CA, Sosa-Urrea JD, Mart\u00ednez-Mu\u00f1oz MA, et al. Prevalence of peripheral neuropathy associated with chemotherapy in four oncology centers of Colombia. Revista De Neurologia. 2019;69(3):94\u20138.","journal-title":"Revista De Neurologia"},{"issue":"2","key":"4256_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/jnci\/djy120","volume":"111","author":"IC Huang","year":"2019","unstructured":"Huang IC, Bhakta N, Brinkman TM, Klosky JL, Krull KR, Srivastava D, et al. Determinants and consequences of financial hardship among adult survivors of childhood cancer: A report from the St. Jude lifetime cohort study. J Natl Cancer Inst. 2019;111(2):189\u2013200.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"4256_CR27","first-page":"892","volume":"16","author":"YY Hong","year":"2019","unstructured":"Hong YY, Xu C, Yu HY, Li XY, Wang Q, Ren LP. Prevalence and predictors of chemotherapy-induced peripheral neuropathy in patients with cancer. Chin J Nurs Educ. 2019;16(12):892\u20136.","journal-title":"Chin J Nurs Educ"},{"issue":"2","key":"4256_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000497233","volume":"14","author":"R Haidinger","year":"2019","unstructured":"Haidinger R, Bauerfeind I. Long-Term side effects of adjuvant therapy in primary breast cancer patients: results of a web-based survey. Breast Care. 2019;14(2):111\u20136.","journal-title":"Breast Care"},{"issue":"5","key":"4256_CR29","first-page":"1","volume":"2019","author":"MS Ezzi","year":"2019","unstructured":"Ezzi MS, Othieno-Abinya NA, Amayo E, Oyiro P, McLigeyo A, Bett Yatich R, et al. Prevalence and predictors of cisplatin-induced peripheral neuropathy at the Kenyatta National hospital. J Global Oncol. 2019;2019(5):1\u20136.","journal-title":"J Global Oncol"},{"issue":"1","key":"4256_CR30","first-page":"S273","volume":"27","author":"H Donovan","year":"2019","unstructured":"Donovan H, Campbell G, Belcher S, Bovbjerg D. Prevalence and predictors of post-treatment peripheral neuropathy in survivors of cancer: results from the 2010 livestrong survey. Support Care Cancer. 2019;27(1):S273.","journal-title":"Support Care Cancer"},{"key":"4256_CR31","doi-asserted-by":"crossref","unstructured":"Zaleta AK, Miller MF, Johnson J, McManus S, Buzaglo JS. Chemotherapy-induced peripheral neuropathy and quality of life among breast cancer survivors. Cancer Res. 2018;78(4).","DOI":"10.1158\/1538-7445.SABCS17-P6-11-08"},{"issue":"6","key":"4256_CR32","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/jnnp-2017-317215","volume":"89","author":"A Shah","year":"2018","unstructured":"Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018;89(6):636\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"4256_CR33","first-page":"S271","volume":"26","author":"J Schilling","year":"2018","unstructured":"Schilling J, Hansen A, Ortner P, Poemmerl M. Patient reported symptoms of cancer treatment and patient satisfaction in BNGO practices-a German survey including the NCCN distress thermometer. Support Care Cancer. 2018;26(2):S271\u20132.","journal-title":"Support Care Cancer"},{"issue":"4","key":"4256_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1590\/1982-0194201800061","volume":"31","author":"MMC Moreira","year":"2018","unstructured":"Moreira MMC, Rodrigues AB, De Oliveira PP, De Aguiar MIF, Da Cunha GH, Pinto RMC, et al. Peripheral neuropathy in people with multiple myeloma. Acta Paul Enferm. 2018;31(4):439\u201345.","journal-title":"Acta Paul Enferm"},{"issue":"2","key":"4256_CR35","first-page":"S98","volume":"26","author":"D Magee","year":"2018","unstructured":"Magee D, Bachtold S, Brown M, Williams J, Farquhar-Smith P. Chemotherapy-induced peripheral neuropathy (CIPN)-a descriptive analysis in a specialist cancer centre. Support Care Cancer. 2018;26(2):S98\u20139.","journal-title":"Support Care Cancer"},{"issue":"8","key":"4256_CR36","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jamaneurol.2018.0963","volume":"75","author":"T Kandula","year":"2018","unstructured":"Kandula T, Farrar MA, Cohn RJ, Mizrahi D, Carey K, Johnston K, et al. Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer clinical, neurophysiological, functional, and patient-reported outcomes. JAMA Neurol. 2018;75(8):980\u20138.","journal-title":"JAMA Neurol"},{"key":"4256_CR37","doi-asserted-by":"publisher","first-page":"ix513","DOI":"10.1016\/S0923-7534(20)34139-9","volume":"23","author":"S Vasquez","year":"2012","unstructured":"Vasquez S, Guidon M, McHugh E, Lennon O, Breathnach OS. Chemotherapy induced peripheral neuropathy: the role of the modified total neuropathy score. Ann Oncol. 2012;23:ix513.","journal-title":"Ann Oncol"},{"issue":"7","key":"4256_CR38","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0883073813491829","volume":"29","author":"P Jain","year":"2014","unstructured":"Jain P, Gulati S, Seth R, Bakhshi S, Toteja GS, Pandey RM. Vincristine-induced neuropathy in childhood all (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol. 2014;29(7):932\u20137.","journal-title":"J Child Neurol"},{"issue":"1","key":"4256_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11845-013-0971-5","volume":"183","author":"S Vasquez","year":"2014","unstructured":"Vasquez S, Guidon M, McHugh E, Lennon O, Grogan L, Breathnach OS. Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice. Ir J Med Sci. 2014;183(1):53\u20138.","journal-title":"Ir J Med Sci"},{"issue":"12","key":"4256_CR40","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.leukres.2013.09.018","volume":"37","author":"E Liew","year":"2013","unstructured":"Liew E, Thyagu S, Atenafu EG, Alibhai SMH, Brandwein JM. Quality of life following completion of treatment for adult acute lymphoblastic leukemia with a pediatric-based protocol. Leuk Res. 2013;37(12):1632\u20135.","journal-title":"Leuk Res"},{"issue":"24","key":"4256_CR41","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1002\/cncr.28340","volume":"119","author":"BL Burnette","year":"2013","unstructured":"Burnette BL, Dispenzieri A, Kumar S, Harris AM, Sloan JA, Tilburt JC, et al. Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. Cancer. 2013;119(24):4308\u201315.","journal-title":"Cancer"},{"issue":"5","key":"4256_CR42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","volume":"46","author":"E Boland","year":"2013","unstructured":"Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA. Living with advanced but stable multiple myeloma: A study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manag. 2013;46(5):671\u201380.","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"4256_CR43","first-page":"S150","volume":"23","author":"A Beijers","year":"2015","unstructured":"Beijers A, Vreugdenhil G, Oerlemans S, Eurlings M, Minnema M, Eeltink C, et al. Chemotherapy-induced peripheral neuropathy in multiple myeloma patients: influence on quality of life and validation of aquestionnaire for daily clinical practice. Support Care Cancer. 2015;23(1):S150.","journal-title":"Support Care Cancer"},{"issue":"3","key":"4256_CR44","first-page":"861","volume":"23","author":"S Padman","year":"2015","unstructured":"Padman S, Lee J, Kumar R, Slee M, Hakendorf P, Richards A, et al. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)\u2014cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. Support Care Cancer. 2015;23(3):861\u20139.","journal-title":"Support Care Cancer"},{"issue":"10","key":"4256_CR45","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s11136-017-1635-0","volume":"26","author":"NB Simon","year":"2017","unstructured":"Simon NB, Danso MA, Alberico TA, Basch E, Bennett AV. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Qual Life Research: Int J Qual Life Aspects Treat Care Rehabilitation. 2017;26(10):2763\u201372.","journal-title":"Qual Life Research: Int J Qual Life Aspects Treat Care Rehabilitation"},{"issue":"9","key":"4256_CR46","first-page":"42","volume":"25","author":"K Webber","year":"2015","unstructured":"Webber K, Sommeijer D, Mileshkin LR, Blagden SP, McAlpine JN, Coleman RL, et al. Obesity, physical inactivity and symptoms after ovarian cancer treatment: results from an international internet-based survey. Int J Gynecol Cancer. 2015;25(9):42\u20133.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"4256_CR47","first-page":"S129","volume":"24","author":"SJ Ahn","year":"2016","unstructured":"Ahn SJ, Choi SY, Jung HJ, Lee YJ, Chu SH. Is obesity an independent risk factor for oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? Support Care Cancer. 2016;24(1):S129.","journal-title":"Support Care Cancer"},{"issue":"6","key":"4256_CR48","first-page":"2411","volume":"24","author":"AJM Beijers","year":"2016","unstructured":"Beijers AJM, Vreugdenhil G, Oerlemans S, Eurelings M, Minnema MC, Eeltink CM, et al. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support Care Cancer. 2016;24(6):2411\u201320.","journal-title":"Support Care Cancer"},{"issue":"3","key":"4256_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5530\/jyp.2016.3.12","volume":"8","author":"EA Imam","year":"2016","unstructured":"Imam EA, Ibrahim A, Palaian S, Ibrahim MIM. Prevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients. J Young Pharmacists. 2016;8(3):239\u201343.","journal-title":"J Young Pharmacists"},{"key":"4256_CR50","doi-asserted-by":"crossref","unstructured":"Ali MKM, Moeller M, Rybicki LA, Moore HCF. Long term peripheral neuropathy symptoms in breast cancer survivors. J Clin Oncol. 2017;35(15).","DOI":"10.1200\/JCO.2017.35.15_suppl.e21599"},{"key":"4256_CR51","doi-asserted-by":"crossref","unstructured":"Kandula T, Farrar M, Kiernan M, Mizrahi D, Carey K, Krishnan A, et al. Long term outcomes and risk factors for chemotherapy induced peripheral neuropathy in childhood cancer survivors. Neurology. 2017;88(16).","DOI":"10.1212\/WNL.88.16_supplement.S46.006"},{"key":"4256_CR52","doi-asserted-by":"crossref","unstructured":"Tay CG, Lee VWM, Ong LC, Goh KJ, Ariffin H, Fong CY. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2017;64(8).","DOI":"10.1002\/pbc.26471"},{"issue":"8","key":"4256_CR53","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.clinph.2020.02.028","volume":"131","author":"HC Timmins","year":"2020","unstructured":"Timmins HC, Li T, Huynh W, Kiernan MC, Baron-Hay S, Boyle F, et al. Electrophysiological and phenotypic profiles of taxane-induced neuropathy. Clin Neurophysiol. 2020;131(8):1979\u201385.","journal-title":"Clin Neurophysiol"},{"issue":"3","key":"4256_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1529-8027.2009.00230.x","volume":"14","author":"S Ramchandren","year":"2009","unstructured":"Ramchandren S, Leonard M, Mody RJ, Donohue JE, Moyer J, Hutchinson R, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripheral Nerv Syst. 2009;14(3):184\u20139.","journal-title":"J Peripheral Nerv Syst"},{"issue":"12","key":"4256_CR55","first-page":"1991","volume":"19","author":"AL Kautio","year":"2011","unstructured":"Kautio AL, Haanp\u00e4\u00e4 M, Kautiainen H, Kalso E, Saarto T. Burden of chemotherapy-induced neuropathy-a cross-sectional study. Support Care Cancer. 2011;19(12):1991\u20136.","journal-title":"Support Care Cancer"},{"issue":"11","key":"4256_CR56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.12788\/jcso.0086","volume":"12","author":"A Beijers","year":"2014","unstructured":"Beijers A, Mols F, Dercksen W, Driessen C, Vreugdenhil G. Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. J Community Supportive Oncol. 2014;12(11):401\u20136.","journal-title":"J Community Supportive Oncol"},{"issue":"8","key":"4256_CR57","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","volume":"18","author":"AK Zaleta","year":"2020","unstructured":"Zaleta AK, Miller MF, Olson JS, Yuen EYN, LeBlanc TW, Cole CE, et al. Symptom burden, perceived control, and quality of life among patients living with multiple myeloma. JNCCN J Natl Compr Cancer Netw. 2020;18(8):1087\u201395.","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"4256_CR58","doi-asserted-by":"crossref","unstructured":"Vivas-Rosales IJ, Garcia-Saavedra L, Martin-Trejo JA, Mejia-Arangure JM, Victorio-Garcia NP, Herrera-Landero A, et al. Chemotherapy-induced peripheral neuropathy in a subpopulation of Mexican pediatric patients with acute lymphoblastic leukemia. Iran J Pediatr. 2017;27(5).","DOI":"10.5812\/ijp.11844"},{"key":"4256_CR59","doi-asserted-by":"publisher","first-page":"637593","DOI":"10.3389\/fphar.2021.637593","volume":"12","author":"M Selvy","year":"2021","unstructured":"Selvy M, Kerckhove N, Pereira B, Barreau F, Nguyen D, Busserolles J, et al. Prevalence of Chemotherapy-Induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: A single center Cross-Sectional study. Front Pharmacol. 2021;12:637593.","journal-title":"Front Pharmacol"},{"key":"4256_CR60","doi-asserted-by":"crossref","unstructured":"Selvy M, Pereira B, Kerckhove N, Gonneau C, Feydel G, P\u00e9torin C ,et al. Long-term prevalence of sensory chemotherapy-induced peripheral neuropathy for 5 years after adjuvant FOLFOX chemotherapy to treat colorectal cancer: a multicenter cross-sectional study. J Clin Med. 2020;9(8).","DOI":"10.3390\/jcm9082400"},{"key":"4256_CR61","doi-asserted-by":"publisher","first-page":"iv198","DOI":"10.1093\/annonc\/mdu333.80","volume":"25","author":"T Beijers","year":"2014","unstructured":"Beijers T, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G. 578P - Adjuvant oxaliplatin dose and dose reductions are associated with severity of peripheral neuropathy among colorectal cancer survivors: results from the Population-Based profiles registry. Ann Oncol. 2014;25:iv198.","journal-title":"Ann Oncol"},{"issue":"2","key":"4256_CR62","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","volume":"9","author":"J Burgess","year":"2021","unstructured":"Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, et al. Chemotherapy-Induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment. Oncol Therapy. 2021;9(2):385\u2013450.","journal-title":"Oncol Therapy"},{"key":"4256_CR63","first-page":"S13","volume":"24","author":"SB Park","year":"2019","unstructured":"Park SB, Alberti P, Kolb NA, Gewandter JS, Schenone A, Argyriou AA. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripheral Nerv Syst. 2019;24:S13\u201325.","journal-title":"J Peripheral Nerv Syst"},{"issue":"1","key":"4256_CR64","first-page":"33","volume":"30","author":"C Teng","year":"2022","unstructured":"Teng C, Cohen J, Egger S, Blinman PL, Vardy JL. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer. Supportive Care Cancer: Official J Multinational Association Supportive Care Cancer. 2022;30(1):33\u201347.","journal-title":"Supportive Care Cancer: Official J Multinational Association Supportive Care Cancer"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04256-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04256-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04256-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:40:48Z","timestamp":1781631648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04256-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4256"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04256-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}